| Cat.No. | Name | Information |
|---|---|---|
| M1692 | CHIR-99021 | CHIR-99021 (CT99021) is an aminopyrimidine derivative that inhibits GSK3α and GSK3β with IC50 values of 10 and 6.7 nM, respectively. |
| M2304 | TWS119 | TWS119 is a GSK-3β inhibitor with IC50 of 30 nM. |
| M1989 | CHIR-99021 HCl | CHIR-99021 HCl (CT99021) is a hydrochloride of CHIR-99021, with IC50 of 10 nM and 6.7 nM for GSK-3α and GSK-3β, respectively. |
| M43378 | GSK-3 inhibitor 4 | GSK-3 inhibitor 4 is an orally active and brain-penetrant inhibitor of GSK-3, CDK2, and CDK5, with IC50 values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM, and 0.68 μM, respectively. |
| M40573 | L807mts | L807mts is a substrate-competitive, potent, and highly selective GSK-3 peptide inhibitor. |
| M39837 | Manzamine A | Manzamine A inhibits specifically GSK-3β and CDK-5 with IC50s of 10.2 μM and 1.5 μM, respectively. Manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A also shows potent activity against HSV-1. |
| M39836 | Manzamine A hydrochloride | Manzamine A hydrochloride inhibits specifically GSK-3β and CDK-5 with IC50s of 10.2 μM and 1.5 μM, respectively. Manzamine A hydrochloride targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A hydrochloride also shows potent activity against HSV-1. |
| M30296 | CHIR 98024 | CHIR 98024 (Compound L) is a glycogen synthase kinase 3 (GSK3) inhibitor with an EC50 of 0.2566 μM. |
| M30050 | GSK-3 Inhibitor XIII | GSK-3 Inhibitor XIII is a potent and ATP-competitive GSK-3 inhibitor with a Ki of 24 nM. |
| M29694 | CHIR-98023 | CHIR-98023 is a potent, selective and reversible inhibitor of GSK3, with IC50s of 10 nM and 6.7 nM for GSK3α and GSK3β, respectively. CHIR-98023 can improve insulin action and glucose metabolism. |
| M29146 | (R)-BRD3731 | (R)-BRD3731 is a GSK3 inhibitor, with IC50 values of 1.05 and 6.7 μM for GSK3β and GSK3α, respectively. |
| M28650 | BRD0209 | BRD0209 is a potent, selective and dual inhibitor of GSK3α/β inhibitor (GSK3α IC50 = 19 nM; GSK3β IC50 = 5 nM). BRD0209 is also a reversible ATP-competitive inhibitor with fast-off kinetics (Ki = 4.2 nM, respectively). BRD0209 is a tricyclic pyrazolotetrahydroquinolinone compound. BRD0209 has the potential for the research of mood disorder diseases. |
| M27698 | ABC1183 | ABC1183 is an orally active selective dual GSK3 and CDK9 inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC50 values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activities. |
| M20836 | Indirubin-3′-oxime | Indirubin-3′-oxime (IDR3O, I3O) is an indirubin analogue that shows favorable inhibitory activity targeting GSK-3β and CDKs. Indirubin-3′-oxime also inhibits JNKs with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM for JNK1, JNK2, and JNK3, respectively. Indirubin-3′-oxime activates Wnt/β-catenin signaling and inhibits adipocyte differentiation and obesity. |
| M20489 | 5-Bromoindole | 5-bromoindole is an important pharmaceutical chemical intermediate and a potential inhibitor of glycogen synthase kinase 3 (GSK-3). |
| M20324 | WAY-333184 | WAY-333184 is a inhibitor of glycogen synthase kinase-3b (GSK-3b). |
| M20308 | WAY-333175 | WAY-333175 is a inhibitor of glycogen synthase kinase-3b (GSK-3b). |
| M20239 | WAY-634931 | WAY-634931 is a inhibitor of GSK3 kinases |
| M20222 | WAY-624687 | WAY-624687 is a GSK3 inhibitor |
| M20198 | WAY-606957 | WAY-606957 is a inhibitor of GSK3 kinases. |
| M20197 | WAY-606956 | WAY-606956 is a inhibitor of GSK3 kinases. |
| M20196 | WAY-606954 | WAY-606954 is a inhibitor of GSK3 kinases. |
| M20192 | WAY-603610 | WAY-603610 is a inhibitor of GSK3 kinases. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
